Indian pharmaceutical firms are flocking to China, after the Asian giant opened its doors to generics and unveiled a raft of favorable regulatory reforms including accepting foreign clinical trial data to support new drug approvals.
Indian Firms May Want To Slow March Into China
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.
